Opko Licenses Protein Biomarker Panel for Prostate Cancer to IHT | GenomeWeb

NEW YORK (GenomeWeb News) – Opko Health today announced it has granted UK-based International Health Technology the rights to offer a novel panel of protein biomarkers and an associated algorithm in parts of Europe for the detection of prostate cancer.

Under the terms of the deal, IHT will offer the biomarker panel in laboratory settings in the UK, Ireland, Sweden, and Denmark. Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.